Evaluation of health economic impact of initial diagnostic modality selection for colorectal cancer liver metastases in suspected patients in China, Japan and the USA

References

• Globocan. Colorectal cancer Fact Sheet 2020. 2020. https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf
   Google Scholar
• Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–259.
   PubMed Web of Science ®Google Scholar
• van der Pool AE, Damhuis RA, Ijzermans JN, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2012;14(1):56–61.
   PubMed Web of Science ®Google Scholar
• Zarour LR, Anand S, Billingsley KG, et al. Colorectal Cancer liver metastasis: evolving paradigms and future directions. Cell Mol Gastroenterol Hepatol. 2017;3(2):163–173.
   PubMed Web of Science ®Google Scholar
• Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019;3(1):50–56.
   PubMed Web of Science ®Google Scholar
• Oliva MR, Saini S. Liver cancer imaging: role of CT, MRI, US and PET. Cancer Imaging. 2004;4(Spec No A):S42–S46.
   PubMedGoogle Scholar
• Chernyak M, Horowitz JM, Kamel IR, et al. ACR Appropriateness Criteria® liver lesion-initial characterization. J Am Coll Radiol. 2020;17(11S):S429–S446.
   PubMedGoogle Scholar
• Guideline JcfTJI. Japanese imaging guideline. 2016. http://www.radiology.jp/content/files/diagnostic_imaging_guidelines_2013_e.pdf
   Google Scholar
• Kaur H, Hindman NM, Al-Refaie WB, et al. ACR Appropriateness criteria(®) suspected liver metastases. J Am Coll Radiol. 2017;14(5s):S314–s325.
   PubMedGoogle Scholar
• Xu J, Fan J, Qin X, et al. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). J Cancer Res Clin Oncol. 2019;145(3):725–736.
   PubMed Web of Science ®Google Scholar
• Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 2010;31(1):19–31.
   PubMed Web of Science ®Google Scholar
• Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257(3):674–684.
   PubMed Web of Science ®Google Scholar
• Asato N, Tsurusaki M, Sofue K, et al. Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases. Jpn J Radiol. 2017;35(4):197–205.
   PubMed Web of Science ®Google Scholar
• Vreugdenburg TD, Ma N, Duncan JK, et al. Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis. Int J Colorectal Dis. 2016;31(11):1739–1749.
   PubMed Web of Science ®Google Scholar
• Zech CJ, Grazioli L, Jonas E, et al. Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden. Eur Radiol. 2009;19(Suppl 3):S753–S763.
   PubMedGoogle Scholar
• Zech CJ, Justo N, Lang A, et al. Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: results from the VALUE trial. Eur Radiol. 2016;26(11):4121–4130.
   PubMed Web of Science ®Google Scholar
• Blankenburg M, Elhamamy M, Zhang D, et al. Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA. J Med Econ. 2022;25(1):1015–1029.
   PubMed Web of Science ®Google Scholar
• He X, Wu J, Holtorf AP, et al. Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China. PLoS One. 2018;13(1):e0191095.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making. 2012;32(5):722–732.
   PubMed Web of Science ®Google Scholar
• Mao Y, Chen B, Wang H, et al. Diagnostic performance of magnetic resonance imaging for colorectal liver metastasis: a systematic review and meta-analysis. Sci Rep. 2020;10(1):1969.
   PubMed Web of Science ®Google Scholar
• Cantisani V, Grazhdani H, Fioravanti C, et al. Liver metastases: contrast-enhanced ultrasound compared with computed tomography and magnetic resonance. World J Gastroenterol. 2014;20(29):9998–10007.
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Watanabe M, Ikehara T, et al. Comparison of contrast-enhanced ultrasonograpy with Gd-EOB-DTPA-enhanced MRI in the diagnosis of liver metastasis from colorectal cancer. J Clin Ultrasound. 2017;4;45(3):138–144.
   PubMed Web of Science ®Google Scholar
• Medicare Provider Utilization and Payment Data: Physician and Other Supplier PUF CY2017 [Internet]. 2017. Available from https://data.cms.gov/Medicare-Physician-Supplier/Medicare-Provider-Utilization-and-Payment-Data-Phy/fs4p-t5eq/data.
   Google Scholar
• RED BOOK Online from Micromedex [Internet]. Available from: http://www.micromedexsolutions.com/.
   Google Scholar
• Database for medical insurance claims and other medical fee information [Internet]. Available from: https://shinryohoshu.mhlw.go.jp/shinryohoshu/searchMenu/.
   Google Scholar
• List of items listed on the NHI drug price standard and information on generic drugs [Internet]. Available from: https://www.mhlw.go.jp/topics/2020/04/tp20200401-01.html.
   Google Scholar
• Goossens N, Singal AG, King LY, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017;8(6):e101–e101.
   PubMed Web of Science ®Google Scholar
• Durand-Zaleski I, Roche B, Fagniez P-L, et al. Economic Implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst. 1997;89(11):790–795.
   PubMedGoogle Scholar
• Chen H, Chen L. Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China. PLoS One. 2017;12(4):e0175189.
   PubMed Web of Science ®Google Scholar
• Nishie A, Goshima S, Haradome H, et al. Cost-effectiveness of EOB-MRI for hepatocellular carcinoma in Japan. Clin Ther. 2017;39(4):738–750.e4.
   PubMed Web of Science ®Google Scholar
• Raoof M, Jutric Z, Haye S, et al. Systematic failure to operate on colorectal cancer liver metastases in California. Cancer Med. 2020;9(17):6256–6267.
   PubMed Web of Science ®Google Scholar
• Roberts KJ, Sutton AJ, Prasad KR, et al. Cost-utility analysis of operative versus non-operative treatment for colorectal liver metastases. Br J Surg. 2015;102(4):388–398.
   PubMed Web of Science ®Google Scholar
• Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.
   PubMed Web of Science ®Google Scholar
• Zech CJ, Korpraphong P, Huppertz A, et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg. 2014 May;101(6):613–621.
   PubMed Web of Science ®Google Scholar
• Kohn CG, Singh P, Korytowsky B, et al. Humanistic and economic burden of hepatocellular carcinoma: systematic literature review. Am J Manag Care. 2019;25(2 Spec No):Sp61–sp73.
   PubMedGoogle Scholar